STOCK TITAN

Belite Bio to Present at the JonesHealthcare Seaside Summit

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Belite Bio (NASDAQ: BLTE), a clinical-stage biopharmaceutical firm specializing in treatments for degenerative retinal diseases, announced that its Chief Scientific Officer, Dr. Nathan Mata, will present a corporate update at the JonesHealthcare Seaside Summit. The event will take place in Encinitas, CA, on July 15, 2024, at 1:00 pm PT. The presentation will be available via webcast on the Belite Bio website under the 'Events' tab, with a replay accessible for 90 days post-presentation.

Positive
  • None.
Negative
  • None.

SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that Dr. Nathan Mata, Chief Scientific Officer of Belite Bio, will participate in the JonesHealthcare Seaside Summit in Encinitas, CA, and present a corporate update on Monday, July 15, 2024, at 1:00 pm PT.

A webcast of the presentation can be accessed under the "Events" tab on the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events. The replay will be archived for 90 days following the presentation date.

About Belite Bio
Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt Disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on TwitterInstagramLinkedInFacebook, or visit us at www.belitebio.com.

Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com

Julie Fallon
belite@argotpartners.com


FAQ

When will Belite Bio present at the JonesHealthcare Seaside Summit?

Belite Bio will present at the JonesHealthcare Seaside Summit on July 15, 2024, at 1:00 pm PT.

Who is presenting at the JonesHealthcare Seaside Summit for Belite Bio?

Dr. Nathan Mata, Chief Scientific Officer of Belite Bio, will present at the event.

How can I access the webcast of Belite Bio's presentation at the JonesHealthcare Seaside Summit?

The webcast can be accessed under the 'Events' tab on the investor relations section of the Belite Bio website.

How long will the replay of Belite Bio's presentation be available?

The replay will be archived for 90 days after the presentation date.

Belite Bio, Inc American Depositary Shares

NASDAQ:BLTE

BLTE Rankings

BLTE Latest News

BLTE Stock Data

2.49B
30.61M
58.6%
0.87%
0.88%
Biotechnology
Healthcare
Link
United States of America
San Diego